IP Library Granted Patent US 8,299,268
Granted Patent B2
US 8,299,268 · App. 13/186,175 · Granted Oct 30, 2012

Methods for preparing diazonamides

Assignees: Board of Regents, The University of Texas System; Joyant Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,299,268
App. No.
13/186,175
Granted
Oct 30, 2012
Kind
B2
Abstract

This invention relates to novel macrocyclic lactams intermediates useful for the preparation of diazonamide analogs. This invention also relates to a novel electrochemical oxidative cyclization for the preparation of such macrocyclic lactams, and their further elucidation to provide diazonamide analogs.

Claims (38)

1. A compound of formula (I):

or a salt thereof; wherein:

R 1 is C1-C4 alkyl;

R 2 is H or Me;

R 3 is —NR 4 R 5 ;

R 4 is H, or C1-C4 alkyl;

R 5 is H, or C1-C8 alkyl, C1-C8 heteroalkyl, C6-C14 arylalkyl, C6-C14 heteroarylalkyl, arylsulfonyl, trialkylsilyl, or alkoxycarbonyl, each of which may be optionally substituted; or —C(═X)R′ where X is O, S, or NH, and R′ is optionally fluorinated C1-C8 alkyl, C2-C8 alkenyl, C5-C12 aryl, or C6-C14 arylalkyl, each of which may be optionally substituted;

R 6 is H, or an arylalkyl, arylsulfonyl, acyl or alkoxycarbonyl;

R 7 is H, or halo, —CN, optionally substituted C1-C6 acyl, —COOR 8 , or —C(O)NR 9 2 ;

R 8 is H, or C1-C8 alkyl, C2-C8 alkenyl, C5-C6 aryl, C6-C14 arylalkyl, or trialkylsilyl;

R 9 is H, or C1-C8 alkyl, C2-C8 alkenyl, C5-C6 aryl, C6-C14 arylalkyl, C6-C14 heteroarylalkyl, —OH, or C1-C4 alkoxy, each of which may be optionally substituted; or two R 9 on the same N can optionally cyclize to form a ring; and

Y′ is H or halo, and Y is halo or —OR 10 , where R 10 is H, or is optionally fluorinated alkylsulfonyl or arylsulfonyl.

2. The compound of claim 1 wherein:

R 1 is isopropyl;

R 2 is H;

R 4 is H;

R 6 is H; and

Y′ is H, and Y is bromo or triflate (-OTf).

3. The compound of claim 1 wherein:

R 7 is H, or halo, —CN, or optionally substituted C1-C6 acyl.

4. The compound of claim 1 wherein:

R 1 is isopropyl;

R 2 is H;

R 4 is H;

R 6 is H;

R 7 is H, or halo, —CN, or optionally substituted C1-C6 acyl; and

Y′ is H, and Y is bromo or triflate (—OTf).

5. The compound of claim 1 having the structure:

wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , Y and Y′ are defined as for formula (I).

6. A compound of a formula selected from the group consisting of:

7. The compound of claim 6 wherein the formula is:

8. The compound of claim 6 wherein the formula is:

9. The compound of claim 6 wherein the formula is:

10. The compound of claim 6 wherein the formula is:

11. The compound of claim 6 wherein the formula is:

12. A compound of a formula selected from the group consisting of:

13. The compound of claim 12 wherein the formula is:

14. The compound of claim 12 wherein the formula is:

Assignments (2)
CONFIRMATORY LICENSE Recorded Aug 9, 2011
From: THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026718/0557 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2011
From: HANSON, GUNNAR; CALDWELL, CHARLES; HARRAN, SUSAN; WEI, QI; ZHOU, MING; HARRAN, PATRICK G.
To: JOYANT PHARMACEUTICALS, INC.; BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 026615/0905 →
Continuity (5)
Continuation 12896898 · Oct 3, 2010
Continuation 12134984 · Jun 6, 2008
Provisional Application 60933916 · Jun 7, 2007
Provisional Application 60954275 · Aug 6, 2007
Related Publication 20120190862A1 · Jul 26, 2012